Robin Guo co-founded and leads LionBio, developing nasal delivery of peptides and biologics using nanoparticle technology from Columbia University. Previously, he was a partner at Andreessen Horowitz and helped establish a16z speedrun; he began his career in McKinsey's pharmaceuticals practice.